Artelinic acid has a lower rate of neurotoxicity than the related artemisinin derivatives arteether and artemether, but is three times more toxic than artesunate. At present, artelinic acid seems unlikely to enter routine clinical use, because it offers no clear benefits over the artemesinins already available (artesunate and artemether).
Artelinic acid has a lower rate of neurotoxicity compared to its related artemisinin derivatives, arteether and artemether, but is three times more toxic than artesunate. Currently, artelinic acid appears unlikely to be used in routine clinical settings due to the lack of clear benefits it offers over existing artemisinin-based treatments (artesunate and artemether).